Compare Halozyme Therapeutics Inc. Common Stock (HALO) vs VNET Group Inc (VNET) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Halozyme Therapeutics Inc. Common Stock vs VNET Group Inc — how do they compare? Halozyme Therapeutics Inc. Common Stock trades at $112.45 (market cap $12.58B), while VNET Group Inc trades at $5.43 (market cap $1.47B). The key difference: Halozyme Therapeutics Inc. Common Stock is far larger — about 8.6× VNET Group Inc's market cap, and Halozyme Therapeutics Inc. Common Stock is trading nearer its 52-week high, VNET Group Inc nearer its low. Which is the better fit depends on your goals.
| HALO | VNET | |
|---|---|---|
Market Cap | $12.58B | $1.47B |
Volume | 2,179,278 | 4,955,295 |
Sector | Health | Technology |
52-Week High | $115.22 | $14.03 |
52-Week Low | $61.63 | $5.13 |
Typical Hold Time | 0 Days | — |
Enterprise Value | $14.49B | $5.04B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
VNET trades at $5.46, up 1.3% today but near 52-week lows, with a bearish technical signal. The company reported a net loss of $256.77 million in 2025, with a negative net income margin of -22.18%, though revenue grew to $9.95 billion. Recent news includes a strategic investment closing and a cooperation agreement with CATL, providing some positive catalysts amid financial challenges.
The outlook remains cautious due to persistent losses and high leverage, but analyst sentiment is moderately bullish with 62.5% buy ratings. Key risks include balance sheet strain from negative cash flow and competitive pressures in the data center market. Upside potential hinges on execution of new partnerships and demand for AI infrastructure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Halozyme Therapeutics Inc. Common Stock
Halozyme Therapeutics develops drug-delivery technologies for biopharmaceutical companies. Its ENHANZE technology uses the rHuPH20 enzyme to support subcutaneous delivery of co-administered medicines.
Read more on HALO →About VNET Group Inc
VNET Group, formerly 21Vianet, is a leading carrier-neutral data center services provider in China. It operates a dual-core strategy: a large-scale retail business serving over 7,000 enterprise customers and an aggressive wholesale segment (Hyperscale 2.0) designed to meet the high-density power and cooling demands of large-scale AI and cloud platforms.
Read more on VNET →
